Catalyst Pharmaceuticals, Inc. completed its merger with Angelini Pharma S.p.A. on July 15, 2026, becoming a wholly owned subsidiary of Parent. Each outstanding share of common stock was canceled and converted into the right to receive $31.50 per share in cash. The company's common stock will be suspended from trading on Nasdaq. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and treatment of rare neuromuscular diseases.

Catalyst Pharmaceuticals, Inc. stockholders at a special meeting held on July 8, 2026, approved the merger proposal to be acquired by Angelini Pharma S.p.A. and its subsidiary, Angelini Cielo Inc. While the merger proposal was approved by a majority of outstanding shares, the non-binding advisory compensation proposal was rejected by stockholders. All current directors are expected to resign upon the effective time of the merger. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of rare neuromuscular diseases.

On June 30, 2026, Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone). The company operates in the pharmaceutical industry and develops treatments for rare diseases.

Catalyst Pharmaceuticals, Inc. announced that the FTC granted early termination of the HSR Act waiting period for its merger with Angelini Pharma S.p.A. and Angelini Cielo Inc. The transaction is expected to close in the third quarter of 2026, pending stockholder approval and other customary closing conditions. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare neurological diseases.